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Summary The improved tumour to non-tumour ratios needed for effective tumour targeting with antibodies
requires that blood background radioactivity is reduced. We investigated the effect of streptavidin as a clearing
agent for '25l-labelled biotinylated anti-CEA antibodies in a human colon carcinoma xenograft model. By
comparing the biodistribution of the monoclonal antibody A5B7 with four, nine or 22 biotins per antibody
molecule, we investigated how the degree of biotinylation of the primary radiolabelled antibody affects its
clearance with streptavidin. Limiting the degree of biotinylation limited blood clearance, whereas nine or 22
biotins per antibody molecule resulted in a 13- to 14-fold reduction in blood radioactivity, the streptavidin-
biotinylated antibody complexes clearing rapidly via the liver and spleen. Although a reduction in tumour
activity was also seen, a 6.6-fold improvement in the tumour to blood ratio was achieved. A comparative
study of streptavidin versus second antibody clearance was carried out using the polyclonal antibody PK4S
biotinylated with 12 biotins per antibody molecule. This study indicated that second antibody was superior for
clearance of the polyclonal antibody, resulting in a larger and faster reduction in blood radioactivity and
improved tumour to blood ratios. In this case the primary antibody was polyclonal, and therefore non-
uniformity of biotinylation may affect complexation with streptavidin. Therefore, the degree of biotinylation
and type of antibody must be carefully considered before the use of streptavidin clearance.
Radioimmunotargeting is limited by the persistence of
radiolabelled antibody in the circulation, which results in low
tumour to blood ratios. This slow antibody clearance from
the blood and non-target tissues delays the time at which
imaging can be carried out, and also therapy is limited by the
potential damage to normal tissues.
To alleviate this problem various clearing strategies have
been used to reduce blood background levels. Investigations
into the administration of a second antibody reactive with
the first, anti-tumour, antibody have been carried out in
animals (Keep et al., 1983; Sharkey et al., 1984, 1988; Pedley
et al., 1989) and in man (Begent et al., 1982, 1987;
Goldenberg et al., 1987), in whom efficient clearing of the
immune complexes formed in the blood is achieved via the
reticuloendothelial system. Another method involves the use
of biotinylated anti-tumour antibodies with avidin (or strep-
tavidin) administered as the clearing agent. This system
utilises the very high affinity of avidin (and streptavidin) for
biotin (Ka = 10-15 M-) (Green, 1970) and also the fast
clearance of avidin-complexed biotinylated antibodies (Sinit-
syn et al., 1989). Avidin-biotin schemes have been used in
various two-step (Kalofonos et al., 1990; Paganelli et al.,
1992; Khawli et al., 1993) and three-step pretargeting
strategies (Paganelli et al., 1990a, 1991) when the radiolabel
is administered separately. Utilisation of avidin as a clearing
agent for circulating radiolabelled biotinylated antibodies
during radioimmunotargeting of tumours has been reported
as a case report for a colorectal cancer patient (Paganelli et
al., 1990b). However, the clearance pattern and effects on
tumour localisation to evaluate the clinical use of clearing
radiolabelled biotinylated antibodies for radioimmuno-
therapy have not been reported.
We have carried out a detailed investigation into the use of
streptavidin as a clearing agent for a radiolabelled
biotinylated anti-CEA antibody, and its effect on tumour
localisation and distribution in normal tissues. We have
investigated whether in vivo distribution and clearance
depend on the biotinylation reaction by comparing forms of
the monoclonal anti-CEA antibody A5B7 with differing
degrees of biotinylation in the mouse LS174T colonic tumour
xenograft model.
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We have also carried out a comparative study to evaluate
whether a streptavidin clearance system is superior to second
antibody clearance. This study involved the use of the poly-
clonal anti-CEA antibody PK4S with donkey anti-sheep as
the second antibody, in comparison with the biodistribution
obtained from biotinylated PK4S cleared with strep-
tavidin.
Materials and methods
Antibody preparation and radiolabelling
Antibodies used were A5B7, a monoclonal murine anti-CEA
(Pedley et al., 1987), and PK4S (PK2G), a polyclonal sheep
anti-CEA (Pedley et al., 1987). Various biotinylation reac-
tions with these anti-tumour antibodies were carried out as
follows:
Caproylamidobiotin-NHS ester (Sigma, Poole, UK) in
DMSO (5 mgml-') was added to A5B7 (1 mgml-' in 0.1 M
sodium bicarbonate buffer, pH 8.5) at molar ratios of 12:1,
24:1 and 66:1 at room temperature for 4 h with constant
gentle agitation. This resulted in A5B7 with approximately
four, nine and 22 biotins per antibody molecule respectively,
estimated using a 4'-hydroxyazobenzene-2-carboxylic acid
(HABA) dye assay (Pierce & Warriner, Chester, UK). This
assay utilises the displacement by biotin in the protein sample
of avidin already bound to HABA dye, thus reducing the
absorbance at 500 nm, and therefore the amount of reactive
biotin in the protein sample can be estimated (Green, 1965).
PK4S was also biotinylated in this way at a 24:1 molar ratio
resulting in approximately 12 biotins per antibody
molecule.
All antibodies were dialysed against PBS, pH 7.4, at 4°C
after completion of the reaction to remove any unreacted
biotinylation reagents. CEA binding after biotinylation was
checked by enzyme-linked immunosorbent assay (ELISA) on
CEA-coated wells. Radiolabelling was carried out with 1251
using chloramine T for 1 min. It is reported that chloramine
T is incompatible with biotin (Budavari, 1989) and therefore
HABA dye assays have been repeated on the protein after
labelling, showing functional biotins after labelling to be
slightly reduced (biotins after labelling are approximately
four, seven and 16 for A5B7 and eight biotins for PK4S).
Donkey anti-sheep second antibody (Wellcome, Dartford,
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UK) was immunopurified on sheep IgG-conjugated
Sepharose beads (Pharmacia, UK) and reactivity with
primary sheep antibody was confirmed by an Ouchterlony
test.
Animal studies
In vil'o testing was carried out with TO nude mice bearing
the LS174T xenograft, established by subcutaneous passaging
from the human colon carcinoma cell line LS174T (Tom et
al., 1976). Both A5B7 and PK4S antibodies have been shown
to localise with this tumour model (Pedley et al., 1991).
Tumour sizes varied, and where possible the range of tumour
size between the groups was matched. The average tumour
size was 0.42 ± 0.29 g.
Streptavidin was chosen over avidin as the clearing agent
because streptavidin is reported to show less non-specific
binding to tissues, thought to be due to its higher isoelectric
point of 10.5 (as opposed to an isoelectric point of 4-5 for
avidin) and the lack of carbohydrate on streptavidin (Hof-
mann et al., 1980).
The radiolabelled first antibody was injected via the tail
vein at a dose of approximately 14jig 14fiCi '25I-labelled
antibody per mouse. Test animals were intraperitoneally
injected with the clearing agent 24 h after the first antibody
injection, at a 10-fold molar excess of the administered dose
of first antibody for streptavidin clearance studies (60 ig of
streptavidin) (Paganelli et al., 1990a) and at a 5-fold molar
excess (70 ig of second antibody) for second antibody
clearance studies (Pedley et al., 1989). Intraperitoneal
administration of the clearing agent was chosen in line with
previous clearance studies by Pedley et al. (1989), in which a
slight improvement in blood clearance with intraperitoneal
injection was seen on comparison with intravenous injection.
In this previous study a dose of five times the first antibody
was found to be optimum for second antibody clearance. A
preliminary experiment to assess whether a 10-fold molar
excess of streptavidin is the optimum dose revealed no
significant difference in biodistribution when a 5-fold excess
was used (data not shown), therefore it should be possible to
reduce the amount of streptavidin used with such a clearance
system in patients and thus decrease both immunogenicity
and cost of the streptavidin. Animals were bled and tissues
removed 1 h and 24 h after clearing agent administration
(25 h and 48 h after first antibody injection). Control animals
without administration of any clearing agents were sacrificed
at the same time points.
The biodistribution data are calculated as percentage
injected dose per gram of tissue (per cent I D g-') and are
mean values of four mice per time point.
Results
Effects ofvarying the degree ofbiotinylation ofthe primary
antibody
Control experiments show no significant difference in biodist-
ribution of the antibodies before and after biotinylation (data
not shown).
Limiting the degree of biotinylation of A5B7 to four
biotins per antibody molecule produced some clearance of
the primary radiolabelled anti-tumour antibody after
administration of streptavidin (Figure 1), resulting in a 40%
reduction in blood radioactivity compared with controls lack-
ing streptavidin. A reduction in both the normal and tumour
tissue radioactivity was seen in a similar proportion to the
decrease in blood activity, and therefore no improvement in
the tumour to blood ratio was achieved.
Increasing biotinylation of the primary antibody
dramatically increased the clearing effect of streptavidin.
Figure 2 shows the typical biodistribution obtained when
biotinylation of A5B7 was increased to nine biotins per
antibody molecule. The earlier time point at 1 h after strep-
tavidin administration (Figure 2a) shows an increase in
biotins per MAb
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Figure 1 Biodistribution of ['25I]A5B7 with four biotins per
MAb 24 h after streptavidin administration (48 h after antibody
injection). Test group (0) was injected with streptavidin 24 h
after antibody injection and compared with animals without
streptavidin administration (U). Results are expressed as percent-
age injected dose per gram of tissue. Vertical bars indicate
s.d.
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Figure 2 Biodistribution of ['25I]A5B7 with nine biotins per
MAb, with (0) and without (-) streptavidin administration at a,
1 h and b, 24 h after streptavidin administration (25 and 48 h
after antibody injection respectively), expressed as percentage
injected dose per gram of tissue. Vertical bars indicate s.d.
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Table I Tumour to blood ratios of ['25I]-biotinylated A5B7 in nude mice bearing LS174T
xenografts, with and without streptavidin administration 24h after antibody injection
Time after 9 biotins/ASB7 22 biotins/A5B7
streptavidin No streptavidin With streptavidin No streptavidin With streptavidin
I h 2.2 3.4 2.2 8.1
24h 2.2 14.5 2.4 15.9
radioactivity in the liver and the spleen as the immune comr
plexes are taken up. At 24 h after streptavidin administration
(48 h after antibody injection) a 14-fold reduction in blood
radioactivity levels to 0.8% I D g-1, in comparison with
control animals, was achieved, as shown in Figure 2b
Although tumour radioactivity was also reduced, from app
roximately 24% to 9% I D g-', the resulting tumour tc
blood ratio is greatly improved from 2.2 to 14.5, as shown ir
Table I.
To determine the effect of further increasing the biotinyla
tion of the primary antibody, the biodistribution of A5B,
with 22 biotins per antibody molecule was investigated. A
difference between these two latter biotinylated antibodies wa
seen 1 h after the streptavidin injection, when a larger decreasc
in blood radioactivity was seen with the more heavily bio
tinylated antibody (Figure 3a) together with a concomitan
large increase in spleen and liver radioactivity levels on clear
ing the complexes formed. Blood radioactivity levels at 11
after streptavidin injection for the A5B7 with 22 biotins wa:
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Figure 3 Biodistribution of ['25I]A5B7 with 22 biotins per MAb,
with (0) and without (O) streptavidin administration at a, 1 h
and b, 24 h after streptavidin administration (25 and 48 h after
antibody injection respectively), expressed as percentage injected
dose per gram of tissue. Vertical bars indicate s.d.
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only 3% I D g-', which is 57% less than the blood radioactiv-
ity obtained with the A5B7 with nine biotins, showing that the
more heavily biotinylated primary antibody was cleared from
the circulation faster after administration of streptavidin.
Figure 3b shows that 24 h after streptavidin administration
the biodistribution of the A5B7 with 22 biotins is very similar
to that of the A5B7 with nine biotins (Figure 2b). A 13-fold
reduction of primary antibody in the circulation to 0.7%
I D g- I was achieved and the tumour radioactivity was
reduced 2.3 times to 8.4% I D g-1, therefore greatly increas-
ing the tumour to blood ratio from 2.4 to 15.9 (Table I).
Comparison ofstreptavidin clearance with second antibody
clearance
It As no second antibody to A5B7 was available, and because a
general anti-mouse antibody cannot be used with a mouse
h model, the comparative streptavidin versus second antibody
S clearance study was carried out using the polyclonal sheep
antibody PK4S. PK4S biotinylated to 12 biotins per antibody
molecule was studied as the primary radiolabelled anti-
tumour antibody with streptavidin clearance. Figure 4 shows
the effect on biodistribution when streptavidin is
administered 24 h after primary biotinylated antibody injec-
tion. Clearance via the liver and spleen again resulted in a
4.5-fold reduction in blood radioactivity to 1.4% I D g-'
24 h after streptavidin administration. Tumour radioactivity
was also reduced in a similar proportion and therefore no
significant improvement in tumour to blood ratio was
observed.
The comparative study with second antibody clearance
gave the results shown in Figure 5. By 1 h after second
antibody administration a 3.2-fold reduction and by 24 h a
13.5-fold reduction of the primary antibody in the blood was
seen. A 3.8-fold decrease in tumour radioactivity resulted,
and thus an improvement in tumour to blood ratio from 1.5
to 5.6 was achieved 24 h after second antibody injection.
With the exception of the A5B7 with four biotins, all the
clearing strategies used have resulted in increased levels of
radioactivity in the liver and spleen. By 24 h after the clear-
ing agent the radioactivity in the liver had decreased to below
control values but splenic radioactivity levels never became
less than those of the controls.
Discussion
We have shown that clearance of circulating biotinylated
primary antibody can be achieved with the administration of
streptavidin. The degree of biotinylation of the antibody
must be optimised in order to obtain the most favourable
tumour to non-tumour ratios.
We have shown that if the level ofbiotinylation ofA5B7 is
limited, then the blood clearance is limited, accompanied by
a similar decrease in tumour radioactivity (Figure 1), thus no
beneficial increase in tumour to non-tumour ratios is
achieved.
When biotinylation of A5B7 was increased to nine or 22
biotins per antibody molecule a 6.6-fold improvement in
tumour to blood ratio resulted 24h after streptavidin
administration (Table I). With the more heavily biotinylated
A5B7 (22 biotins per antibody molecule) a greater decrease
in circulatory radioactivity was seen 1 h after streptavidin
than that seen with the A5B7 with nine biotins. This faster
clearance is thought to occur because the greater availability
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Figure 4 Biodistribution of '251-labelled biotinylated PK4S with
(0) and without (-) streptavidin administration at a, I h and b,
24 h after streptavidin administration (25 and 48 h after antibody
injection respectively), expressed as percentage injected dose per
gram of tissue. Vertical bars indicate s.d.
of biotin on ASB7 with 22 biotins per antibody molecule
means that larger immune complexes can be formed with the
streptavidin, and they can be expected to clear faster than
smaller complexes. This is a favourable result with respect to
reducing the risk of myelotoxicity in radioimmunotherapy
caused by prolonged retention of radioactivity in the blood,
but the resultant large increase in the liver and splenic uptake
is undesirable. Twenty-four hours after streptavidin administ-
ration these levels are reduced to near-control radioactivity
levels in the spleen and less than control values for the liver.
Although myelotoxicity, which is reported as the dose-
limiting toxicity in patients (Ettinger et al., 1982), would be
reduced, further time points to evaluate the dose to the
spleen need to be studied in order to evaluate possible splenic
toxicity. The spleen is a less radiosensitive organ than the
bone marrow, and therefore this high, but possibly transient,
activity may present only a minor problem.
The ability of avidin to clear biotinylated antibodies from
the circulation was first reported by Sinitsyn et al. (1989),
who showed an increase in liver and splenic uptake of
biotinylated antibody-avidin complexes, which is in agree-
ment with our data. A preliminary study for radioim-
munoguided surgery by Paganelli et al. (1990b) showed that
avidin administration after radiolabelled biotinylated
antibody injection resulted in successful blood clearance in a
patient, although the radioactivity level in other tissues was
not reported. Avidin has also been used successfully by Norr-
gren et al. (1993) to reduce circulating 125I-biotinylated anti-
tumour antibody via extracorporeal immunoadsorption on
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Figure 5 Biodistribution ofb125I]PK4S with (O) and without (0)
second antibody administration at a, I h and b, 24 h after second
antibody administration (25 and 48h after primary antibody
injection respectively), expressed as percentage injected dose per
gram of tissue. Vertical bars indicate s.d.
an agarose-avidin column, resulting in improved tumour to
non-tumour ratios.
Work by Paganelli et al. (1990a, 1991) has been carried out
to improve tumour targeting by using cold biotinylated
antibodies to tar'get the tumour followed by clearance with
avidin or streptavidin before administration of the biotin-
conjugated radiolabel (three-step pretargeting). Although
improved tumour to non-tumour ratios have been reported,
this method involves a more complicated protocol to ensure
correct timings of injections in order to achieve the optimal
dose.
It is important to assess whether clearance with strep-
tavidin finproves on second antibody clearance. Results from
our comparative second antibody versus streptavidin study
indicate that the second antibody clearance system was
superior, as improved tumour to blood ratios resulted (5.6
for second antibody clearance compared with 2.0 for strep-
tavidin clearance). The reduction in blood radioactivity levels
seen with streptavidin clearance was not as large, or as fast,
as the clearance seen with second antibody, where blood
radioactivity was reduced 13.5-fold 24h after second anti-
body administration (Figure 5b). However, this may be be-
cause the primarv antibodyv in this casep wvas polyclonnal and
therefore not uniformly biotinylated (some molecules may
have little or no biotin attached), thus a proportion of the
radiolabelled antibody was unable to complex with strep-
tavidin and clear, leaving a residual amount of primary
antibody in the circulation. On the present evidence strep-
tavidin is not the preferred system for the clearance of poly-506 D. MARSHALL et al.
clonal antibodies, and in this situation second antibody
clearance would be more advantageous. A direct comparison
with monoclonal antibodies was not possible, but strep-
tavidin does have the advantage of being applicable to
antibodies of different types and to antibody fragments. Both
second antibody and streptavidin are likely to be
immunogenic in man, but the use of immunosuppressive
drugs may overcome this (Ledermann et al. (1988).
We have shown that streptavidin clearance of primary
biotinylated monoclonal antibody will give preferential
tumour to blood ratios important for radioimmunotherapy
(Table I). Unfortunately, in all the streptavidin clearance
strategies carried out the radioactivity associated with the
tumour was reduced, which was also seen with second
antibody clearing strategies by Pedley et al. (1989) and
Sharkey et al. (1988). Although absolute tumour uptake
values are decreased, this can be overcome by increasing the
dose of radioactivity initially injected, thus ensuring tumour
radioactivity remains high enough after clearance for effective
therapy while blood levels are reduced to minimise myelotox-
icity. This was shown by Blumenthal et al. (1989), who
demonstrated that, in a comparative study of radiolabelled
primary antibody alone and primary antibody at double the
dose plus second antibody clearance, the latter gave imp-
roved therapy but without any increase in toxicity.
Biotinylation is a mild procedure (Bayer & Wilchek, 1990)
and should be universally applicable to most monoclonal
antibodies as the biotin NHS-ester incorporates via lysine
residues which are numerous in most proteins. Although the
biotinylated antibodies used for this series of experiments
had reduced amounts of biotin after radiolabelling with
chloramine T, radiolabelling of biotinylated antibodies has
now been carried out using lodo-gen (Fraker & Speck, 1978).
We have found that this gentler method of radiolabelling
with iodine does not have an adverse effect on the biotins
conjugated to the protein and is therefore recommended for
any future iodinations of biotinylated antibodies. We are
therefore encouraged that biotinylation and streptavidin
clearance of A5B7 and other monoclonal anti-tumour
antibodies can be optimised and successfully used in the
clinic.
A5B7 was kindly provided by Celltech Limited, Slough, UK. This
work was supported by the Cancer Research Campaign.
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